Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Yoshida N, Hattori N, Nakamura H, Sato A, Kawaguchi A, Sueoka-Aragane N, Kojima K, Okada S, Ushijima T, Kimura S, Sueoka E. Watanabe T, et al. Among authors: fukuda kurahashi y. Blood. 2020 Aug 13;136(7):871-884. doi: 10.1182/blood.2019003084. Blood. 2020. PMID: 32391874 Free article.
Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.
Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y, Fukuda-Kurahashi Y, Yoshida-Sakai N, Hattori N, Hayashi Y, Kawaguchi A, Tohyama K, Okada S, Harada H, Ushijima T, Kimura S. Ureshino H, et al. Among authors: fukuda kurahashi y. Mol Cancer Ther. 2021 Aug;20(8):1412-1421. doi: 10.1158/1535-7163.MCT-20-1125. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045225 Free PMC article.
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.
Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, Fukuda-Kurahashi Y, Hayashi Y, Hirai H, Yamashita S, Ushijima T, Okada S, Kimura S. Kamachi K, et al. Among authors: fukuda kurahashi y. Cancer Lett. 2022 Feb 1;526:273-283. doi: 10.1016/j.canlet.2021.11.032. Epub 2021 Dec 4. Cancer Lett. 2022. PMID: 34875342 Free article.
Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y, Watanabe T, Yamamoto Y, Ureshino H, Kamachi K, Yoshida-Sakai N, Fukuda-Kurahashi Y, Yamashita S, Hattori N, Nakamura H, Kawaguchi A, Ushijima T, Sueoka E, Kimura S. Kurahashi Y, et al. Among authors: fukuda kurahashi y. Blood Adv. 2023 Apr 25;7(8):1545-1559. doi: 10.1182/bloodadvances.2022008362. Blood Adv. 2023. PMID: 36516085 Free PMC article.
A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.
Kawasoe K, Watanabe T, Yoshida-Sakai N, Yamamoto Y, Kurahashi Y, Kidoguchi K, Ureshino H, Kamachi K, Fukuda-Kurahashi Y, Kimura S. Kawasoe K, et al. Among authors: fukuda kurahashi y. Cancers (Basel). 2023 Oct 21;15(20):5089. doi: 10.3390/cancers15205089. Cancers (Basel). 2023. PMID: 37894456 Free PMC article.
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.
Watanabe T, Yamamoto Y, Kurahashi Y, Kawasoe K, Kidoguchi K, Ureshino H, Kamachi K, Yoshida-Sakai N, Fukuda-Kurahashi Y, Nakamura H, Okada S, Sueoka E, Kimura S. Watanabe T, et al. Among authors: fukuda kurahashi y. Blood Adv. 2024 Mar 26;8(6):1345-1358. doi: 10.1182/bloodadvances.2023011131. Blood Adv. 2024. PMID: 38190613 Free PMC article.